{"url_path":"/sec/rvph/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 ** **EXHIBITS**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1742927/0001437749-26-016762-index.html","accession_number":"0001437749-26-016762","cik":"0001742927","ticker":"RVPH","issuer_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1742927/0001437749-26-016762-index.html","primary_entity_key":"0001742927","primary_entity_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"word_count":428,"has_tables":true,"body_markdown":"**ITEM 6.** **EXHIBITS**\n\n \n\n**Exhibit No.**\n\n \n\n**Exhibit**\n\n \n \n \n\n4.1\n\n \n\n[Form of Pre-Funded Warrant (incorporated by reference from Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on March 19, 2026).](http://www.sec.gov/Archives/edgar/data/1742927/000143774926009063/ex_935004.htm)\n\n4.2\n\n \n\n[Form of Series G Warrant (incorporated by reference from Exhibit 4.2 to the Company’s Current Report on Form 8-K filed with the SEC on March 19, 2026).](http://www.sec.gov/Archives/edgar/data/1742927/000143774926009063/ex_935005.htm)\n\n4.3\n\n \n\n[Form of Series H Warrant (incorporated by reference from Exhibit 4.3 to the Company’s Current Report on Form 8-K filed with the SEC on March 19, 2026).](http://www.sec.gov/Archives/edgar/data/1742927/000143774926009063/ex_935006.htm)\n\n10.1\n\n \n\n[Form of Securities Purchase Agreement (incorporated by reference from Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on March 19, 2026).](http://www.sec.gov/Archives/edgar/data/1742927/000143774926009063/ex_935007.htm)\n\n10.2\n\n \n\n[Placement Agency Agreement, dated March 18, 2026, between Reviva Pharmaceuticals Holdings, Inc. and A.G.P./Alliance Global Partners (incorporated by reference from Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on March 19, 2026).](http://www.sec.gov/Archives/edgar/data/1742927/000143774926009063/ex_935008.htm)\n\n31.1*\n\n \n\n[Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a)](ex_954660.htm)\n\n31.2*\n\n \n\n[Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a)](ex_954661.htm)\n\n32.1**\n\n \n\n[Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350](ex_954662.htm)\n\n101.INS*\n\n \n\nInline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document\n\n101.SCH*\n\n \n\nInline XBRL Taxonomy Extension Schema Document\n\n101.CAL*\n\n \n\nInline XBRL Taxonomy Extension Calculation Linkbase Document\n\n101.DEF*\n\n \n\nInline XBRL Taxonomy Extension Definition Linkbase Document\n\n101.LAB*\n\n \n\nInline XBRL Taxonomy Extension Label Linkbase Document\n\n101.PRE*\n\n \n\nInline XBRL Taxonomy Extension Presentation Linkbase Document\n\n104*\n\n \n\nCover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)\n\n \n\n*\n\nFiled herewith.\n\n \n\n**\n\nThe certifications furnished in Exhibit 32.1 hereto are deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and will not be deemed to be incorporated by reference into any filing under such Act or the Securities Act of 1933, as amended, except to the extent that the registrant specifically incorporates such certifications by reference.\n\n \n\n16\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\n**Reviva Pharmaceuticals Holdings, Inc.**\n\n(Registrant)\n\n \n \n\n \n \n\n \n \n\nDate: May 13, 2026\n\nBy: /s/ Laxminarayan Bhat\n\n \n\nLaxminarayan Bhat\n\n \n\n*Chief Executive Officer*\n\n \n\n*(Principal Executive Officer)*\n\n \n \n\nDate: May 13, 2026\n\nBy: /s/ Narayan Prabhu\n\n \n\nNarayan Prabhu\n\n \n\n*Chief Financial Officer*\n\n \n\n*(Principal Financial and Accounting Officer)*\n\n \n\n17"}